雷美替胺：撤销上市申请。雷美替胺治疗失眠症：出于患者最佳利益撤销上市申请。
Ramelteon: application withdrawn. Ramelteon in insomnia: withdrawal of marketing application in patients' best interests.
出版信息
Prescrire Int. 2009 Jun;18(101):114.
PMID:19639675
Abstract
The European Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the use of the melatonin receptor agonist ramelteon in insomnia, due to its unfavourable risk-benefit balance. In France, melatonin itself is licensed for use in this indication.
摘要
欧洲人用药品委员会（CHMP）已就褪黑素受体激动剂雷美替胺用于失眠症一事发布了否定意见，因其风险效益比不佳。在法国，褪黑素本身被批准用于这一适应症。
Zotero 插件